Please login to the form below

Not currently logged in

Gilead wins European approval for triple hep C combination Vosevi

The treatment brings together sofosbuvir, velpatasvir and voxilaprevir

GileadGilead Sciences has chalked up a big win with its hepatitis C treatment Vosevi (sofosbuvir/velpatasvir/voxilaprevir) as it becomes the first and only single tablet regimen for patients who have previously failed therapy with direct-acting antivirals (DAA).

The drug was approved to treat adults with genotype 1-6 chronic hepatitis virus (HCV) infection as a 12-week regimen for patients without cirrhosis or with compensated cirrhosis.

Supported by data from two phase III studies, POLARIS-1 and POLARIS-4 evaluated 12 weeks of the single tablet regimen in patients with hepatitis C genotypes 1-6 who were previously treated unsuccessfully with DAA-containing regimens, including NS5A inhibitors.

The results show that 97% of patients on Vosevi achieved the primary efficacy endpoint of a sustained viral response (SVR) for 12 or more weeks post-treatment.

John Milligan, president and chief executive officer, Gilead, said: “The authorisation of Vosevi demonstrates our ongoing commitment to bring therapies with high cure rates to all HCV-infected patients.”

The EC also approved an extension for Harvoni (ledipasvir/sofobuvir), - which was previously authorised to treat adults with chronic HCV genotypes 1, 3, 4, 5, or 6 - and will now include the treatment in adolescents aged 12 to 18 years.

This marks another win for the biopharma as Harvoni is the first DAA chronic HCV treatment to be granted an extension to treat adolescents in the European Union.

Milligan added: “We look forward to working with healthcare providers and government to ensure Vosevi is made available to patients who would benefit the most from it, while continuing to expand the benefits of our other approved medicines for patients with chronic HCV infection across Europe.”

Vosevi has already had the US Food and Drug Administration (FDA) go-ahead back in July for the re-treatment of adults with genotype 1-6 chronic HCV infection.

Article by
Gemma Jones

25th October 2017

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...